{
    "nct_id": "NCT05838716",
    "official_title": "High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients",
    "inclusion_criteria": "* Be diagnosed with Stage I-IV prostate cancer without metastases to bone (lymph node involvement and prior diagnosis of a primary cancer is allowed)\n* Be age 60 years or older\n* Be starting ADT or have received their first ADT treatment in the past 3 months, with at least 6 planned months of treatment remaining (both luteinizing hormone-releasing hormone (LHRH) antagonists and LHRH agonists are permitted)\n* Have a total serum vitamin D between 10 and 27 ng/ml\n* Have an total serum calcium of less than or equal to 10.5 mg/dl\n* Have a normal GFR (glomerular filtration rate)\n* Agree not to take calcium and/or vitamin D supplements for the duration of the intervention other than those provided by the study\n* Be able to provide written informed consent\n* Be able to swallow pills and capsules\n* Be able to speak and read English\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 60 Years",
    "exclusion_criteria": "* Have long term (greater than 3 months) use of any pharmacologic bone-modifying agent including but not limited to oral or IV bisphosphonates, denosumab, or teriparatide prior to enrollment\n* Have a diagnosis of stage IV chronic kidney disease\n* Have a diagnosis of grade II or greater hypercalcemia (serum calcium greater than 10.5 mg/dl)\n* Have a history of hypercalcemia or vitamin D toxicity/sensitivity",
    "miscellaneous_criteria": ""
}